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OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Does 
Adalimumab improve symptoms in patients with moderate to severe Hidradenitis Suppurativa?” 
 
STUDY DESIGN: A systematic review of three peer-reviewed articles published between 2011 
and 2016 which present patient oriented evidence.  
 
DATA SOURCES: Review incorporated analysis of two randomized controlled trials (RCTs) 
and one open label prospective trial. Studies were selected based upon the relevance to the 
clinical question, does adalimumab usage improve symptoms in individuals with moderate to 
severe hidradenitis suppurativa.  
 
OUTCOMES MEASURED: The outcomes measured focused on patient reported reduction in 
hidradenitis suppurativa symptoms. Two studies analyzed outcomes using patient reported 
Dermatology Life Quality Index (DLQI) scores, which take into account both physical and 
psychological disease burden as reported by the patient. The third study evaluated outcomes by 
analyzing the percentage of participants whom reported at least a 30% reduction in pain scores 
following adalimumab usage.  
 
RESULTS: The open label trial completed by Sotiriou E, Goussi C, Lallas A, et al. revealed a 
significant improvement (P= 0.001) in patient reported DLQI scores following adalimumab 
usage for 24 weeks when compared to their initial DLQI scores. The study completed by Miller 
I, Lynggaard CD, Lophaven S, et al. failed to show statistically significant improvement in DLQI 
scores of patients receiving adalimumab compared to those receiving a placebo. The study by 
Kimball AB, Okun MM, Williams DA, et al. revealed inconsistent results concerning patient 
reported pain improvement with adalimumab use versus the use of a placebo. 
 
CONCLUSION: Review of the three studies selected revealed inconclusive results. Though the 
results were inconsistent between studies, the presence of positive results in two of the studies 
indicates that further investigation of the efficacy of adalimumab use for hidradenitis suppurativa 
is warranted. Results from the studies analyzed indicate further research should also be carried 
out to evaluate the efficacy of simultaneous adalimumab and conventional therapeutic usage.  
 















Hidradenitis suppurativa (HS) is a dermatologic condition characterized by the formation 
and recurrence of painful skin nodules, lesions, and sinus tracts that can progress to severe 
scarring.1 Patients not only suffer from the visible dermatologic manifestations of HS, but also 
the subsequent acute and chronic inflammatory states caused by the presence of these 
abnormalities.1 HS patients must grapple with its physical effects as well as its psychological 
effects, which are brought about by the chronic pain patients experience alongside feelings of 
embarrassment secondary to the visible signs of the disease.2 These combined physical and 
psychological sequelae can have a profound effect on the lives of individuals with HS.  The fact 
that HS greatly affects the quality of patients’ lives and no gold standard therapeutic regimen has 
been agreed upon, has led to a multitude of studies evaluating a range of treatment options taking 
place with the goal of finding a final solution. This review analyzes three studies that attempted 
to determine whether adalimumab is a potential final solution for HS patients.  
 
 HS has an incidence of 11.4 per 100,000 people in the United States.3 With its severe 
effects, HS must be a differential considered by healthcare providers across primary care fields 
as well as dermatologists. HS must also be therapeutically managed by these fields and by 
general surgery in more severe cases. Apart from the physical effects, studies have also indicated 
that HS patients suffer monetary effects, spending an average of $5,048 on medications annually, 
while also incurring greater costs and more frequent visits to the emergency room in comparison 
to control groups.4 The latest estimates obtained through analysis of data from 2002 to 2010 
indicated that there were about 254,000 health care visits per year addressing HS.5 Overall, 
Eck, Adalimumab use for Hidradenitis Suppurativa 2 
despite its low prevalence the multispecialty involvement, financial impact, and associated 
decreases in quality of life make HS a relevant healthcare topic. 
 The exact cause of HS has not been agreed upon to this point, but the most well 
supported theory is that HS is the result of chronic follicular occlusion of the 
folliculopilosebaceous units of the skin.1 The occlusion of these units leads to their distention as 
they fill with keratinocytes and potential antigens, and these distended units are thought to be the 
foundation and cause of the characteristic skin nodules and lesions associated with HS.1 
Subsequent force on the distended units can lead to rupture and dispersal of their contents which 
in turn lead to an inflammatory response. This inflammatory response leads to the formation of 
sinus tracts and scarring as well as acute and chronic pain.1 HS more commonly effects the 
intertriginous areas of the body due to the persistent friction and pressure at these locations.1 This 
increased friction and pressure at intertriginous areas causes a greater number of follicular unit 
ruptures to occur followed by increased inflammation and scarring compared to other sites.  
 No “gold standard” therapy has been agreed upon for HS, and this absence of definitive 
treatment has fueled the testing and usage of many therapies. One of the first forms of 
management used in HS, as with many disease, is lifestyle changes including weight loss and 
smoking cessation.6 Data analysis has revealed obese and current smokers are more likely to 
develop and experience more severe and progressive HS, so limiting these factors can provide 
great benefit.1 The application of antiseptic solutions and antimicrobial lotions at lesion and 
nodule sites is an early option, though this approach does not halt the formation or recurrence of 
nodules and lesions.6 Initial pharmacologic options including topical antibiotics, such as 
clindamycin, oral antibiotics, and retinoids are used to reduce the chances of infection at active 
open HS sites and attempt to provide symptom relief.6 Intra-lesional steroid injection is another 
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therapeutic measure used to relieve inflammation and attempt to decrease subsequent sinus tract 
formation and severe scarring.6 Surgical debridement and excision of active inflammatory 
lesions and sinus tracts is a late option considered in uncontrolled HS.1  
 The above therapies have provided inconsistent results and varying levels of symptom 
relief. This inconsistency has led to biologic medications, such as adalimumab, being considered 
as a treatment option for HS.6 With the most significant effects of HS being associated with the 
immune system’s inflammatory response to follicular rupture,1 therapies which can mediate this 
response have become a focus. Adalimumab, a tumor necrosis factor(TNF) alpha inhibitor 
medication, is an immunosuppressant.6 Its administration is intended to lead to a less 
exaggerated immune and thus inflammatory response to the rupture of the follicular units formed 
in HS, and these therapeutic effects are thought to lead to a decrease in sinus tract formation, 
chronic inflammation, and severe scarring associated with HS.6 
Objective 
The objective of this selective evidence based medicine (EBM) review is to determine 
whether or not “Does Adalimumab improve symptoms in patients with moderate to severe 
Hidradenitis Suppurativa?” 
Methods  
The three studies used in this systematic review consisted of two double blind 
randomized controlled trials and one open label perspective trial. These studies were selected 
based upon their relevance to the clinical question posed in this review, and their presentation of 
trial results as patient oriented evidence. The population evaluated in each of the three studies 
consisted of both men and women over the age of 18 with clinically diagnosed moderate to 
severe HS.7,8,9 Two of the studies use the intervention of 40 mg of adalimumab subcutaneously 
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weekly,7,9 while the other study had an intervention of 40 mg of adalimumab given 
subcutaneously once every two weeks.8 The duration of the studies varied from 12 to 48 weeks. 
Comparison within the two randomized controlled trials was done by administering visually 
matched placebos to the control group at the same intervals as the groups receiving 
adalimumab.8,9 No comparison group was used in the open label perspective trial.7 In all studies 
selected, patient reported changes in HS symptoms were the outcomes measured.  
 The keywords “hidradenitis suppurativa” and “adalimumab” were used in PubMed to 
find the studies used within this review. The studies selected were all published in English and 
appeared in peer reviewed journals. The inclusion criteria used for the selection of studies 
included being peer reviewed, being published after 2010, and presenting outcomes as patient 
oriented evidence. Studies presenting non-dichotomous data were analyzed using statistics 
including: p-values, z-scores, confidence interval (CI), and mean changes from baseline.7,8 
Statistics including number needed to treat (NNT), absolute benefit increase (ABI), and relative 
benefit increase (RBI) were used for the analysis of the study containing dichotomous data.9  
Table 1 - Demographics & Characteristics of included studies 
Study Type # Pt Age(
yrs) 










18 years of age or older 
with clinically diagnosed 
moderate to severe 
hidradenitis suppurativa. 
HS must have been 
present for at least 2 
years, and patients have 
tried and failed at least 3 
systemic treatments. 
No treatment with 
biologic medications 
within in 6 months of the 
trial start date. Patients 
could not have chronic 
or recurrent infection or 
chronic systemic 
diseases. 
0 80 mg of 
Adalimumab 
given at base 
then one 40 
mg injection- 












Men and women of at 
least 18 years of age with 
clinically diagnosed 
moderate to severe 
hidradenitis suppurativa. 
Participants must have 
No treatment with 
biologic medications 
within 6 months or 
conventional treatment 
within 4 weeks. Patients 
could not have chronic 
5 80 mg of 
Adalimumab 
given at base 
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had hidradenitis 
suppurativa for at least 6 
months. 
or recurrent infection or 
chronic systemic 
diseases. 













18 years or older with 
clinically diagnosed 
moderate to severe 
hidradenitis suppurativa 
and an inadequate 
response to oral antibiotic 
treatment. 
Participants could not 
have taken oral 
antibiotics within 28 
days of baseline in trial 
1. No other exclusion 
criteria were specified. 
37 Adalimumab 







 The outcomes evaluated in this review are patient oriented outcomes (POEMs) reported 
within the selected studies. These results were reported by the patients in the respective studies 
and focused on HS symptom relief brought about by adalimumab usage. The studies by Sotiriou 
et al. and Miller et al. reported outcomes using patient reported Dermatology Life Quality 
Index(DLQI) scores. DLQI is a scale with a maximum score of 30 that attempts to quantify the 
physical pain, impact on daily life, and psychological effects of a dermatological disease 
experienced by an individual. Outcomes were based upon comparisons of mean DLQI scores at 
baseline with subsequent scores reported by participants throughout the studies. Outcome 
evaluation in the study by Kimball et al. consisted of analyzing the percentage of participants 
who reported at least a 30% reduction in pain and at least a 1-unit reduction from baseline in the 
pain score as rated on a 0 to 10 scale following the usage of adalimumab.  
Result 
 Sotiriou et al. conducted an open-label perspective study done at Aristotle University in 
Greece. Of the 20 individuals screened for the study, 15 were selected based upon the inclusion 
and exclusion criteria seen in Table 1.7 Qualifying patients were informed of the purpose and 
design of the study prior to its start, and all participants underwent the intervention being 
evaluated.7  
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 All participants received a subcutaneous dose of 80 mg of adalimumab at baseline, 
followed by 40 mg doses given weekly for a 24-week period.7 The DLQI scores of participants 
were obtained at baseline, after 24 weeks of adalimumab administration, and after an additional 
24-week washout period. The mean DLQI scores of all participants were calculated at these 
intervals and were found to be 15.9, 4.8, and 12.2 respectively.7 The change in mean DLQI score 
between these intervals was evaluated to determine the effect of adalimumab use. The change 
from 15.9 at baseline to 4.8 at the end of the 24-week period of adalimumab usage was found to 
be significant (∆= -11.1, P = 0.001, Z = -3.415), indicating a statistically significant 
improvement in symptoms with adalimumab use.7 The change in mean DLQI scores from 4.8 at 
the end of 24 weeks to 12.2 after the washout period was also found to be significant (∆= 7.4, P= 
0.001, Z= -3.423), indicating a significant worsening of symptoms with the cessation of 
adalimumab.7 The change from the baseline value of 15.9 to the washout period value of 12.2 
was found to be significant (∆= -3.7, P= 0.005, Z= -2.817), indicating prolonged symptom relief 
after cessation.7 Based upon the analysis of change in mean DLQI score in this study 
adalimumab usage  provided a recognizable improvement in HS symptoms, and statistically 
significant worsening of symptoms was also seen with the discontinuation of adalimumab. This 
analysis is highlighted in Table 2. No major adverse effects were noted throughout the duration 
of the study, all participants completed the full therapeutic regimen, and all participants reported 
at the end of the washout period.7  
Table 2: Change in Mean DLQI scores following administration of adalimumab and 
washout period from Sotiriou et al.7 
 Baseline End of 24 Weeks  End of 48 Weeks 
Mean DLQI Score 15.9 4.8 12.2 
Change in Mean DLQI 
Score from Baseline 
-  -11.1(P= 0.001, Z= -3.415)        -3.7 (P= 0.005, Z= -2.817) 
Change in Mean DLQI 
Score from 24 weeks 
-  -  + 7.4 (P= 0.001, Z=-3.423) 
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 Miller et al. conducted a double blind randomized control trial completed at Roskilde 
Hospital and Gentofte Hospital in Denmark. 21 patients were selected for the trial based upon the 
same inclusion and exclusion criteria as the Sotiriou et al. study, except pregnant women could 
also participate in this trial. Computer randomization was used to assign participants to the 
experimental and control groups at a 2.5:1 ratio, meaning over twice as many participants 
received adalimumab (15) as opposed to those receiving a placebo (6).8  
Patients in the experimental group received 80 mg of adalimumab subcutaneously at 
baseline followed by 40 mg doses given every other week for twelve weeks. Members of the 
control group were given visually matched placebos at these same intervals.8 Participants were 
then followed for an additional 12-week washout period for continued evaluation.  Changes in 
mean DLQI scores were used to measure outcomes in this study, and these values were obtained 
at baseline, 12 weeks, and 24 weeks.8 The experimental group mean DLQI scores at these 
intervals were 16.07, 12.40, and 16.70 respectively, while the control group scores were 8.33, 
9.33, and 9.00 respectively. The changes in mean DLQI score for the experimental group were    
-3.67 from baseline to 12 weeks and 0.53 from baseline to the end of the washout period, 
compared to changes of 1.00 and 0.67 seen in the control group over these intervals.8 These 
scores and differences can be found highlighted in Table 3. Statistical comparison of the changes 
in mean DLQI scores experiences by the experiment and control groups were used to determine 
the significance of the study results. Comparison of the changes in mean DLQI scores from 
baseline to 12 weeks between these two groups revealed a p-value of 0.06, and comparison from 
baseline to completion of the washout period revealed a p-value of 0.88. These results revealed 
no significant difference based upon the threshold of P ≤ 0.05, and thus the trial failed to show 
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an improvement in HS with adalimumab usage versus a placebo. Based on these results it can be 
inferred that adalimumab usage did not provide significant symptom relief. 
 By the conclusion of the study 5 participants had dropped out due to worsening HS 
symptoms, 3 from the experimental group and 2 from the control group.8 The study indicates the 
main adverse effects experienced by participants were mild infection and nonspecific rash.8 In 
the case of individuals who dropped out of the study, the last recorded data point for that 
individual was carried forward and used as the reported value at each subsequent interval.  
Table 3: Change in Mean DLQI scores from Miller et al.8 
 Baseline End of 12 Weeks  End of 24 Weeks 
Mean DLQI Score  Experimental Group: 
16.07 (CI: 12.13 to 20.00) 
Control Group:     
8.33 (CI: 4.66 to 12.01) 
Experimental Group: 
12.40 (CI: 7.79 to 17.09) 
Control Group:     
9.33 (CI: 3.75 to 14.91) 
Experimental Group: 
16.70 (CI: 12.50 to 20.70) 
Control Group:     
9.00 (CI: 3.61 to 14.39) 
Change in Mean DLQI 
Score from Baseline 
-  Experimental Group:        
-3.67 (CI: -8.99 to 1.66) 
Control Group:     
1.00 (CI: -1.39 to 3.39) 
Experimental Group:  
0.53 (CI: -4.66 to 5.73) 
Control Group:     
0.67 (CI: -2.56 to 3.90) 
Significance of Mean 
DLQI Change between 
Experimental and Control 
Groups 
-  P = 0.06 P = 0.88 
 
 Kimball et al. completed two large double-blind randomized controlled trials which took 
place across 14 different countries at over 200 different sites. Between the two trials a total of 
907 people were screened and 633 qualified to participate in the study. The inclusion and 
exclusion criteria were again similar to those of the Sotiriou et al. study. Although, in this study 
participants were not required to have failed other treatment regimens prior to entering, and in 
the second trial patients could continue other antibiotic therapies.9 In both trials the participants 
were randomly assigned to the experimental and control groups at a 1:1 ratio.9  
  The study consisted of several phases in which participants were reassigned to various 
groups and given numerous different interventions. For the purposes of consistently, only the 
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initial phases of each trial from this study will be evaluated for this systematic review. In both 
trials the experimental groups were given weekly doses of 40 mg adalimumab subcutaneously, 
while the control groups were given a visually matched placebo weekly.9 Outcomes were 
considered positive if, after 12 weeks of adalimumab use, participants reported a 30% or greater 
reduction in pain and at least a 1-unit reduction from baseline in pain score as rated on a 0 to 10 
scale.9 This evaluation only included individuals who reported pain scores of 3 or higher at the 
onset of the study.9  In the initial trial 27.9% of the experimental group reported qualifying pain 
reduction compared to 24.8% of the control group (P = 0.63).9 Analysis of this dichotomous data 
yields an RBI of 12.5%, an ABI of 3.1%, and an NNT of 33. In the second trial 45.7% of the 
experimental group versus 20.7% of the control group reported qualifying pain improvement (P= 
0.001).9 This equates to an RBI of 131%, an ABI of 25.9%, and an NNT of 4. The data from the 
initial trial indicates that for every 33 individuals treated with adalimumab one additional group 
member will recognize a noticeable benefit in comparison to a group of 33 treated with a 
placebo, whereas the results from the second trial indicate that an additional benefit would be 
seen using groups of only 4 individuals. The results of the second trial indicate adalimumab 
usage is much more efficacious than those of the first. For calculation purposes, no value was 
entered in the case of participants who withdrew, thus calculations function as if the participants 
had never been a part of the trials.9 
Table 4: Change in Pain Score from Kimball et al.9 
 Experimental Group Qualifying Pain 
Reduction 
Control Group Qualifying 
Pain Reduction 
ABI RBI NNT 
Trial 1 27.9% (34/122) 24.8%(27/109) 3.1% 12.5% 33 
Trial 2 45.7%(48/105) 20.7%(22/111) 25.9% 131% 4 
 
The study indicated that 17 of the initial 307 participants in the first trial and 20 of 448 
participants in the second trial failed to complete the full duration of the phase being evaluated. 
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Reasons for the 37 total withdrawals included adverse effects (9), loss to follow up (6), withdraw 
of consent (16), and other (6).9 The most common adverse effect noted during the study was 
infection.9 In the first trial 28.3% of the experimental group versus 24.8% of the control group 
experienced infections, while 25.2% of the experimental group and 32.5% of the control group 
experiencing infections in the second trial.9 This data does not appear to show an increased 
chance of infection with the usage of adalimumab for a 12-week period compared to usage of a 
placebo, though 12 weeks is a short period when considering adverse effect development.  
Discussion 
 Of the three studies evaluated for this review the study by Sotiriou et al. revealed the 
most consistent and statistically significant benefits of adalimumab usage, but this trial was also 
an open label trial in which the participants were informed of the goals of the study beforehand.7 
Prior knowledge that the intervention was being received could have played a role in the positive 
results reported by the patients. In the Miller et al. study, the large variance in initial mean DLQI 
scores between the experimental and control groups must be considered as a factor with the 
potential to effected results.8 Another variable of note is that the largest study, Kimball et al., was 
sponsored by a manufacturer of adalimumab.9 The sponsor was involved in the construction of 
the study and made aware of all results prior to the publication.9 The manufacturer’s involvement 
may have led to a preferential set up towards positive results. This study also yielded inconsistent 
results, with the first trial having a NNT of 33 versus a NNT of 4 found in the second trial.9 
Though, the second trial obtained more promising results the individuals in this trial could 
continue other conventional therapies while also receiving adalimumab. This difference in 
parameters between trials can greatly effect results and the ability to attribute positive results 
solely to the use of adalimumab. 
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 Along with efficacy, the financial feasibility and potential adverse effects of a product 
must be considered prior to its implementation. A recent study published in 2018 evaluating the 
costs of conventional therapies compared to adalimumab for HS treatment revealed an average 
yearly cost of € 8,309.60 for conventional therapies versus €3,264.20 for adalimumab.10 This 
indicates that adalimumab usage may be the more cost-effective option, but this study was also 
partially funded by the adalimumab manufacturer.10 Concerning safety, though the studies in this 
review revealed no consistent adverse effects with adalimumab usage, adalimumab is an 
immunosuppressant with a black box warning for increased chances of developing serious 
infections as well as lymphoma and other malignancies.11 Continued evaluation of the adverse 
effects seen with long term adalimumab use must be analyzed to determine whether the potential 
benefits outweigh the risks of therapy.  
Conclusion 
 Based upon the above review of three clinical studies it is inconclusive whether 
adalimumab improves symptoms in individuals with moderate to severe HS. Only one study 
revealed consistent statistically significant improvement of HS symptoms with adalimumab use.7 
Of the other two studies, one revealed inconsistent result as discussed above9 and the other failed 
to show a significant improvement with the use of adalimumab.8 These inconsistent results may 
be attributable to the large differences in study designs, but the presence of positive results in 
some trials indicates that further studies should be done concerning the efficacy of adalimumab 
use in HS. In future trials, further investigation should be done evaluating whether the use of 
adalimumab concomitantly with different conventional therapies is more beneficial than the use 
of single agents alone. The results of the second trial in the final study discussed indicate this 
may be a more efficacious approach.9 
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